JP2010534684A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534684A5
JP2010534684A5 JP2010518431A JP2010518431A JP2010534684A5 JP 2010534684 A5 JP2010534684 A5 JP 2010534684A5 JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010534684 A5 JP2010534684 A5 JP 2010534684A5
Authority
JP
Japan
Prior art keywords
seq
composition according
amino acid
acid sequence
cationic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010518431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534684A (ja
JP5401457B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/071350 external-priority patent/WO2009015385A1/en
Publication of JP2010534684A publication Critical patent/JP2010534684A/ja
Publication of JP2010534684A5 publication Critical patent/JP2010534684A5/ja
Application granted granted Critical
Publication of JP5401457B2 publication Critical patent/JP5401457B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010518431A 2007-07-26 2008-07-28 抗菌ペプチド、組成物及びその使用方法 Expired - Fee Related JP5401457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26
US60/952,059 2007-07-26
PCT/US2008/071350 WO2009015385A1 (en) 2007-07-26 2008-07-28 Antimicrobial peptide, compositions , and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013222846A Division JP5965884B2 (ja) 2007-07-26 2013-10-28 抗菌ペプチド、組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2010534684A JP2010534684A (ja) 2010-11-11
JP2010534684A5 true JP2010534684A5 (enExample) 2011-06-02
JP5401457B2 JP5401457B2 (ja) 2014-01-29

Family

ID=40281862

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010518431A Expired - Fee Related JP5401457B2 (ja) 2007-07-26 2008-07-28 抗菌ペプチド、組成物及びその使用方法
JP2013222846A Expired - Fee Related JP5965884B2 (ja) 2007-07-26 2013-10-28 抗菌ペプチド、組成物及びその使用方法
JP2016132290A Pending JP2017002057A (ja) 2007-07-26 2016-07-04 抗菌ペプチド、組成物及びその使用方法
JP2018153719A Active JP6722241B2 (ja) 2007-07-26 2018-08-17 抗菌ペプチド、組成物及びその使用方法
JP2020105975A Pending JP2020169190A (ja) 2007-07-26 2020-06-19 抗菌ペプチド、組成物及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013222846A Expired - Fee Related JP5965884B2 (ja) 2007-07-26 2013-10-28 抗菌ペプチド、組成物及びその使用方法
JP2016132290A Pending JP2017002057A (ja) 2007-07-26 2016-07-04 抗菌ペプチド、組成物及びその使用方法
JP2018153719A Active JP6722241B2 (ja) 2007-07-26 2018-08-17 抗菌ペプチド、組成物及びその使用方法
JP2020105975A Pending JP2020169190A (ja) 2007-07-26 2020-06-19 抗菌ペプチド、組成物及びその使用方法

Country Status (24)

Country Link
US (1) US8623811B2 (enExample)
EP (3) EP3120862B1 (enExample)
JP (5) JP5401457B2 (enExample)
KR (4) KR101717275B1 (enExample)
CN (2) CN101842107B (enExample)
AU (1) AU2008278593B2 (enExample)
BR (3) BR122019000266B1 (enExample)
CA (1) CA2694046C (enExample)
CO (1) CO6260098A2 (enExample)
CR (1) CR11239A (enExample)
CY (2) CY1118503T1 (enExample)
DK (2) DK3120862T3 (enExample)
ES (2) ES2609914T3 (enExample)
HR (1) HRP20161722T1 (enExample)
HU (1) HUE031136T2 (enExample)
IL (3) IL203173A (enExample)
LT (1) LT2178549T (enExample)
MX (1) MX2010000916A (enExample)
NZ (1) NZ582459A (enExample)
PL (1) PL2178549T3 (enExample)
PT (2) PT2178549T (enExample)
SG (1) SG188128A1 (enExample)
SI (1) SI2178549T1 (enExample)
WO (1) WO2009015385A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090102833A (ko) * 2006-12-29 2009-09-30 레반스 테라퓨틱스, 아이엔씨. 역서열 ｈｉｖ-ｔａｔ 폴리펩티드를 이용한 수송 분자
PL2178549T3 (pl) * 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN102356091A (zh) 2008-03-14 2012-02-15 阿勒根公司 基于免疫的血清型a肉毒杆菌毒素活性测定
SMT201800215T1 (it) 2008-12-31 2018-05-02 Revance Therapeutics Inc Formulazioni iniettabili di tossina botulinica domanda di brevetto correlata
EP2413947B1 (en) * 2009-04-01 2020-04-29 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
LT2440231T (lt) 2009-06-10 2020-01-10 Nono Inc. Agento, prijungto prie tat internalizacijos peptido, įvedimas kartu su putliųjų ląstelių degranuliacijos inhibitoriumi
KR101975051B1 (ko) * 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
JP7029805B2 (ja) 2015-09-17 2022-03-04 コントラフェクト コーポレイション グラム陰性菌に対して活性を有する溶解素ポリペプチド
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
CN110198703A (zh) * 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤
EP4132468A4 (en) * 2020-04-08 2024-04-17 Amicrobe, Inc. COMPOSITIONS AND USES OF LOCALLY APPLIED SYNTHETIC AMINO ACID POLYMERS FOR THE PREVENTION AND TREATMENT OF VIRUS INFECTIONS
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025072381A1 (en) 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ATE169822T1 (de) * 1992-04-23 1998-09-15 Allelix Biopharma Behandlung von herpesvirus infektion
ES2123062T3 (es) 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
AU685862B2 (en) * 1993-10-22 1998-01-29 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
DE69434319T3 (de) 1993-12-28 2011-02-17 Allergan, Inc., Irvine Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6191254B1 (en) * 1995-08-23 2001-02-20 University Of British Columbia Antimicrobial cationic peptides
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
AU1818299A (en) * 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
EP1044280A1 (en) * 1997-12-12 2000-10-18 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS
CA2347828A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
CA2354044A1 (en) 1998-12-10 2000-06-15 Washington University Protein transduction system and methods of use thereof
HRP20010309B1 (en) 1998-12-23 2005-06-30 Idea Ag Improved formulation for topical non-invasive application in vivo
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
EP1401473B1 (en) 2001-02-16 2009-07-29 Cellgate Inc. Transporters comprising spaced arginine moieties
CA2446458A1 (en) * 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
MXPA04005611A (es) * 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
ZA200602754B (en) * 2003-09-12 2007-06-27 Univ British Columbia Effectors of innate immunity determination
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
US8974774B2 (en) * 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CA2558408C (en) * 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1927597B1 (en) * 2004-08-18 2016-11-02 Novabiotics Limited Antibacterial peptides
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
US20080207522A1 (en) 2004-11-12 2008-08-28 Hancock Robert E W Antimicrobial Peptides
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
AU2006218455A1 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
MX2007010673A (es) 2005-03-03 2008-04-07 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
WO2006105450A2 (en) 2005-03-30 2006-10-05 Revance Therapeutics, Inc. Compositions and methods for treating acne
US8518414B2 (en) 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
NZ598039A (en) 2006-12-29 2013-08-30 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
KR20090102833A (ko) 2006-12-29 2009-09-30 레반스 테라퓨틱스, 아이엔씨. 역서열 ｈｉｖ-ｔａｔ 폴리펩티드를 이용한 수송 분자
PL2178549T3 (pl) * 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
SMT201800215T1 (it) 2008-12-31 2018-05-02 Revance Therapeutics Inc Formulazioni iniettabili di tossina botulinica domanda di brevetto correlata

Similar Documents

Publication Publication Date Title
JP2010534684A5 (enExample)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2011136981A5 (enExample)
JP2013507132A5 (enExample)
JP2010088434A5 (enExample)
JP2007045829A5 (enExample)
WO2008093060A3 (en) Peptides and their use
JP2012126742A5 (enExample)
JP2017048194A5 (enExample)
JP2011155981A5 (enExample)
WO2007149542A3 (en) Antimicrobial kinocidin compositions and methods of use
WO2007122581A3 (en) Compositions and kits of phenylephrine
JP2009225798A5 (enExample)
JP2011177189A5 (enExample)
NZ612161A (en) Radiolabled her2 binding peptides
JP2013523703A5 (enExample)
UA118167C2 (uk) Пептид та його застосування
EP2039366A4 (en) COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
EA201001014A1 (ru) Фармацевтически приемлемые соли метил (3-{[[3-(6-амино-2-бутокси-8-оксо-7,8-дигидро-9h-пурин-9-ил)пропил](3-морфолин-4-илпропил)амино]метил}фенил)ацетата и их применение в терапии
WO2013000922A9 (en) Ccr2 antagonist peptides
JP2013539454A5 (enExample)
DE602005008996D1 (de) Radiofluorierte peptide
WO2008093058A3 (en) Peptides and their use
TW200942524A (en) Novel aminomethyl benzene derivatives
JP2015533791A5 (enExample)